Fidelity International
RARE icon

Fidelity International’s Ultragenyx Pharmaceutical RARE Stock Holding History

Fidelity International’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-217,014
Closed -$22.2M – 531
2015
Q2 		$22.2M Sell
217,014
-300,000
-58% -$23.3M 0.07% 250
2015
Q1 		$32.1M Sell
517,014
-517,014
-50% -$28.7M 0.1% 187
2014
Q4 		$45.4M Hold
1,034,028
– – 0.16% 147
2014
Q3 		$58.5M Buy
+1,034,028
New +$52M 0.22% 115

Other funds holding RARE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fidelity International's RARE Position: Q3 2015 in Review

Fidelity International sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2015, closing a stake of 217,014 shares — an estimated $22.2M sold.

Fidelity International first reported a position in RARE in Q3 2014 and held it in 4 quarters. The position peaked at $58.5M in Q3 2014. 161 funds tracked by Wall St. Rank hold RARE as of Q3 2015.

  • Fidelity International reported no remaining Ultragenyx Pharmaceutical position as of Q3 2015 after selling out during the quarter.
  • Fidelity International sold 217,014 Ultragenyx Pharmaceutical shares in Q3 2015, an estimated $22.2M.
  • Fidelity International first reported a position in Ultragenyx Pharmaceutical in Q3 2014 and held it in 4 quarters.
  • Fidelity International's Ultragenyx Pharmaceutical position peaked at $58.5M in Q3 2014.
  • 161 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2015.

Based on Fidelity International's 13F filing for Q3 2015, filed 10 Nov 2015.